tiprankstipranks
Blurbs

Barclays Keeps a Hold Rating on Beam Therapeutics (BEAM)

Barclays analyst Gena Wang maintained a Hold rating on Beam Therapeutics (BEAMResearch Report) on May 9 and set a price target of $38.00. The company’s shares closed last Tuesday at $35.78, close to its 52-week low of $32.90.

According to TipRanks.com, Wang is a 5-star analyst with an average return of 13.4% and a 45.4% success rate. Wang covers the Healthcare sector, focusing on stocks such as Crispr Therapeutics AG, Vertex Pharmaceuticals, and Arcturus Therapeutics.

Currently, the analyst consensus on Beam Therapeutics is a Moderate Buy with an average price target of $92.17, a 156.5% upside from current levels. In a report issued on May 9, J.P. Morgan also maintained a Hold rating on the stock with a $102.00 price target.

See the top stocks recommended by analysts >>

Based on Beam Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $51.07 million and GAAP net loss of $64.71 million. In comparison, last year the company earned revenue of $6,000 and had a GAAP net loss of $95.46 million.

Based on the recent corporate insider activity of 38 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BEAM in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Beam Therapeutics, Inc. develops and commercializes DNA base editing technologies for the treatment of human disease. Its licensed technology platform, which includes access to base editing technologies and associated technologies that enhance the scope of base editing. The company was founded by David R. Liu, Feng Zhang and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.

Read More on BEAM:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles